Stay updated with breaking news from Zeneca Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Detailed results from the PROVENT Phase III pre-exposure prophylaxis trial showed that AstraZeneca’s Evusheld, formerly AZD7442, reduced the risk of...
21.04.2022 - Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary ...
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the...
Investegate announcements from AstraZeneca PLC, Evusheld Positive EU CHMP Opinion
Investegate announcements from AstraZeneca PLC, Update on US review of Fasenra in nasal polyps